Ding Yan, Yan Jia-Lai, Fang An-Ning, Zhou Wei-Feng, Huang Ling
Clinical Laboratory, The Second Affiliated Hospital of Southeast University, Nanjing, Jiangsu, China.
Department of Medical Technology, Anhui Medical College, Hefei, Anhui, China.
Oncotarget. 2017 Jul 4;8(39):66402-66413. doi: 10.18632/oncotarget.18949. eCollection 2017 Sep 12.
The diagnostic value and suitability of circulating miRNAs for the detection of hepatocellular carcinoma have been inconsistent in the literature. A meta-analysis is used to systematically evaluate the diagnostic value of circulating miRNAs. Eligible studies were selected and the heterogeneity was assessed by subgroup analysis, meta-regression, and publication bias. After strictly and comprehensive screening, the source methods, internal reference and the cut-off values of the included miRNAs were first listed. Circulating miRNAs demonstrated a relatively good diagnostic value in hepatocellular carcinoma, In the subgroup analysis, diagnosis odds ratio showed a higher accuracy with multiple miRNAs than with a single miRNA as well as with serum types than plasma types. In addition, although miRNAs have many expression patterns, the high frequency expression miRNAs (miR-21, miR-199 and miR-122) might be more specific for the diagnosis of hepatocellular carcinoma.The sources of heterogeneity might be related to the number of miRNAs and the specimen types in meta-regression. Furthermore, it's surprised that the pooled studies were first demonstrated publication bias ( < 0.05). In conclusion, multiple miRNAs in serum have a better diagnostic value, and the publication bias was stable. To validate the potential applicability of miRNAs in the diagnosis of hepatocellular carcinoma, more rigorous studies are needed to confirm these conclusions.
循环miRNA用于检测肝细胞癌的诊断价值和适用性在文献中一直存在不一致的情况。本荟萃分析旨在系统评估循环miRNA的诊断价值。筛选符合条件的研究,并通过亚组分析、荟萃回归和发表偏倚评估异质性。经过严格全面的筛选后,首先列出了纳入miRNA的来源方法、内参及截断值。循环miRNA在肝细胞癌中显示出相对较好的诊断价值。在亚组分析中,诊断比值比显示,多种miRNA联合诊断的准确性高于单一miRNA,血清样本类型的诊断准确性高于血浆样本类型。此外,尽管miRNA有多种表达模式,但高频表达的miRNA(miR-21、miR-199和miR-122)可能对肝细胞癌的诊断更具特异性。在荟萃回归中,异质性来源可能与miRNA数量和样本类型有关。此外,令人惊讶的是,首次发现纳入的研究存在发表偏倚(P<0.05)。综上所述,血清中的多种miRNA具有更好的诊断价值,且发表偏倚稳定。为验证miRNA在肝细胞癌诊断中的潜在适用性,需要更严格的研究来证实这些结论。